NCT04751539CompletedPhase 1
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AND017 Following Oral Single and Multiple Dose Administration
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Kind Pharmaceuticals LLC
- Enrollment
- 78
- Locations
- 1
- Primary Endpoint
- Safety evaluations
Study Overview
Brief Summary
This is a phase I, randomized, double-blind, placebo-controlled, dose-escalation study in healthy subjects to evaluate safety, tolerability, PKs and PDs of AND017 following oral single and multiple dose administration.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Sequential
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 45 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •BMI within 18.0-30.0 kg/m2 (inclusive)
- •Blood Pressure (BP) and 12-lead electrocardiogram (ECG) showing no clinically significant abnormalities during screening;
- •No clinically significant abnormal values in physical examination, clinical laboratory tests, liver function or kidney function;
Exclusion Criteria
- •Current or chronic history of liver disease or known hepatic or biliary abnormalities, including but not limited to ALT, alkaline phosphatase and bilirubin >1.5xULN (isolated bilirubin>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%);
- •Subjects with Hb: male <120 g/L or >160 g/L, female <110 g/L or >150 g/L;
- •Subjects with any abnormalities of hematology during screening: Mean corpuscular volume (MCV), platelet count, serum iron, ferritin;
- •Subjects with a history of medical treatment or disease likely to increase the risk of bleeding or disturbance of blood coagulation;
- •History of deep vein thrombosis, stoke, transient ischemic attack, pulmonary embolism or other thrombosis-related condition within the last five years;
- •History of myocardial infarction, heart failure or acute coronary syndrome;
- •Evidence of active peptic, duodenal or esophageal ulcer disease at screening;
- •History of pulmonary artery hypertension;
- •History of sensitivity to heparin or heparin-induced thrombocytopenia;
- •Subjects with major illness or surgery within past 3 months prior to screening, or planned surgery during study;
- •Known or suspected history of drug abuse within the past 5 years or presence of drug abuse within 3 months before study;
- •Donated blood >400 mL or significant blood loss equivalent to 400 mL or received blood transfusion within 3months of screening; or donated blood >200 mL or significant blood loss equivalent to 200 mL within 1 month prior to screening.
- •Participation in any clinical study with an investigational drug, biologic or device within 4 weeks or 5 times the half-life of the specific drug/biologics (whichever is longer), prior to dosing;
Arms & Interventions
Placebo
Placebo Comparator
Placebo administrated once on Day 1 in Part A or daily from Day 1 to Day 10 in Part B
Intervention: Placebo (Drug)
AND017 single dose escalation
Experimental
Subjects will be administrated with single dose of AND017 capsule from 1 mg to 50 mg during Part A.
Intervention: AND017 single dose (Drug)
AND017 repeated dose escalation
Placebo Comparator
Subjects will be administrated with repeated dose of AND017 from 4 mg to 30 mg for 10 consecutive days during Part B.
Intervention: AND017 multiple dose (Drug)
Outcomes
Primary Outcomes
Safety evaluations
Time Frame: 17 Days
Incidents of AE and abnormal laboratory tests
Secondary Outcomes
- Plasma Cmax of AND017(1 day)
- Plasma CL/F of AND017(1 day)
- Plasma CLss/F of AND017(10 days)
- Plasma %AUCex of AND017(1 day)
- Plasma λz of AND017(1 day)
- Plasma Css,max of AND017(10 days)
- Plasma Css,avg of AND017(10 days)
- Plasma Vss/F of AND017(10 days)
- Plasma t1/2 of AND017(1 day and 10 days)
- Plasma Rac(AUC) of AND017(10 days)
- PD parameters(17 days)
- Plasma Tmax of AND017(1 day and 10 days)
- Plasma AUC of AND017(1 day and 10 days)
- Plasma Vz/F of AND017(1 day)
- Plasma MRT of AND017(1 day)
- Plasma Css,min of AND017(10 days)
- Plasma DF of AND017(10 days)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
A Phase I Study of GZR18 Injection in Obese/Overweight SubjectsOverweight and ObesityNCT06548945Gan and Lee Pharmaceuticals, USA16
Completed
Phase 1
Study of Safety, Tolerability, and Pharmacokinetics of REGN3470-3471-3479 in Healthy Adult VolunteersHealthy VolunteersNCT02777151Regeneron Pharmaceuticals24
Completed
Phase 1
A Dose-escalation Study of LPM3480392 in Chinese Healthy SubjectsHealthyNCT05862974Luye Pharma Group Ltd.80
Completed
Phase 1
A Study to Evaluate the Safety and Efficacy of DDO-3055 in Healthy Volunteers and Patients With Chronic Kidney DiseaseChronic Kidney DiseaseNCT03976115Jiangsu HengRui Medicine Co., Ltd.54
Completed
Phase 1
A Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability and Pharmacokinetics of AVLX-144Safety IssuesToleranceNCT04689035Avilex Pharma46